Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study

被引：0
|
作者：
Yasushi Goto
Nobuyuki Yamamoto
Elizabeth T. Masters
Hironori Kikkawa
Jack Mardekian
Robin Wiltshire
Kanae Togo
Yuichiro Ohe
机构：
[1] National Cancer Center Hospital,Department of Thoracic Oncology
[2] Wakayama Medical University,Department of Internal Medicine
[3] Health Economics and Outcomes Research,Medical Affairs, Oncology
[4] Pfizer Inc,Oncology Global Medical Affairs
[5] Pfizer Japan Inc,undefined
[6] Statistics,undefined
[7] Pfizer Inc.,undefined
[8] Pfizer Ltd,undefined
[9] Corporate Affairs,undefined
[10] Health and Value,undefined
[11] Pfizer Japan Inc.,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Advanced non-small cell lung cancer; Alectinib; Anaplastic lymphoma kinase; Crizotinib; Medical data vision; Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3311 / 3323
页数：12
相关论文
共 50 条
  • [21] The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
    Heo, Ja Yoon
    Park, Changhee
    Keam, Bhumsuk
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Se Hyun
    Kim, Yu Jung
    Lee, Jong Seok
    Heo, Dae Seog
    THORACIC CANCER, 2019, 10 (11) : 2117 - 2123
  • [22] Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
    Rijavec, Erika
    Biello, Federica
    Indini, Alice
    Grossi, Francesco
    Genova, Carlo
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2022, 14 : 1 - 9
  • [23] Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
    James E. Frampton
    Drugs, 2013, 73 : 2031 - 2051
  • [24] Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
    Frampton, James E.
    DRUGS, 2013, 73 (18) : 2031 - 2051
  • [25] Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
    Zhao, Min
    Liu, Shu
    Xie, Rui
    Zhang, Jianjun
    Li, Jiang
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (12) : 1309 - 1316
  • [26] Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study
    Guan, Maojing
    Xu, Jianping
    Shi, Qingming
    CANCER GENETICS, 2023, 270-271 : 32 - 38
  • [27] Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer
    Del Valle, Maria Fatima Flores
    Chang, Alex Yuang-Chi
    JOURNAL OF THORACIC DISEASE, 2019, 11 (09) : 3864 - 3873
  • [28] Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer
    Dagogo-Jack, I.
    Shaw, A. T.
    Riely, G. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (05) : 625 - 633
  • [29] Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
    Koizumi, Tomonobu
    Fukushima, Toshirou
    Gomi, Daisuke
    Kobayashi, Takashi
    Sekiguchi, Nodoka
    Sakamoto, Akiyuki
    Sasaki, Shigeru
    Mamiya, Keiko
    CASE REPORTS IN ONCOLOGY, 2016, 9 (01): : 212 - 215
  • [30] Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer
    Xu, Y.
    Ji, D.
    Pan, P.
    Li, T.
    Han, L-X.
    Zhang, Z.
    Wang, Y.
    Li, H.
    Chen, X-F.
    Zheng, X-J.
    Xu, L.
    Liu, H-X.
    Meng, Q-H.
    Wang, M-Z.
    Zheng, Q-S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1086 - S1086
12345